Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis

Leptomeningeal metastasis (LM) is a significant complication that advances fast and has a poor prognosis for patients with advanced non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. Current therapies for LM are inconsistent and ineffective, and establishe...

Full description

Bibliographic Details
Main Authors:	Caiyan Jia, Qian Xu, Lu Zhao, Fanming Kong, Yingjie Jia
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Translational Oncology
Subjects:	Leptomeningeal metastasis Epidermal growth factor receptor EGFR tyrosine kinase inhibitors Non-small cell lung cancer Osimertinib
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523323002188

Similar Items

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
by: Yali Yi, et al.
Published: (2022-03-01)

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study
by: Xia Wang, et al.
Published: (2021-07-01)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
by: Matthew G. Field, et al.
Published: (2022-06-01)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
by: Byoung Soo Kwon, et al.
Published: (2020-02-01)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
by: Mei-Mei Zheng, et al.
Published: (2022-05-01)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
by: Lei Wen, et al.
Published: (2023-08-01)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of <i>EGFR</i>-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable <i>EGFR</i> Mutations in Cerebrospinal Fluid
by: Pei-Ya Liao, et al.
Published: (2022-06-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
by: Leydis Luna Torres, et al.
Published: (2021-10-01)

Analysis of Clinicopathological Feature and Prognosis for  Leptomeningeal Metastasis in Non-small Cell Lung Cancer
by: Min ZHU, et al.
Published: (2016-08-01)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
by: Chun-Ta Huang, et al.
Published: (2023-03-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing
by: Hainan Yang, et al.
Published: (2022-05-01)

Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review
by: Wenjuan Zhong, et al.
Published: (2024-04-01)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
by: Qiuyue Ye, et al.
Published: (2023-05-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report
by: Kai Wu, et al.
Published: (2022-01-01)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
by: Ting Chen, et al.
Published: (2023-10-01)

The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
by: Ainur F. Nasretdinov, et al.
Published: (2022-11-01)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
by: YanRu Qin, et al.
Published: (2020-08-01)

Heterogeneity or transformation? A whack‐a‐mole case of EGFR‐mutant lung adenocarcinoma and small cell carcinoma: A case report
by: Taira Ninomaru, et al.
Published: (2022-08-01)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
by: Jing Liu, et al.
Published: (2019-07-01)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
by: Ping-Chih Hsu, et al.
Published: (2023-10-01)

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
by: K K Laktionov, et al.
Published: (2018-06-01)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
by: Chia-Yu Kuo, et al.
Published: (2022-12-01)

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
by: Tai-Huang Lee, et al.
Published: (2022-06-01)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
by: Donatella Romaniello, et al.
Published: (2020-08-01)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ
Published: (2017-11-01)

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis
by: Weiwei Yan, et al.
Published: (2019-09-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Successful Management of Neuroblastoma with Leptomeningeal Metastasis: An Interesting Case
by: Babak Abdolkarimi, et al.
Published: (2020-04-01)

Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy
by: Sahrun Sahrun, et al.
Published: (2019-10-01)

Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
by: Ning Li, et al.
Published: (2022-01-01)

Diagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung Cancer
by: Yan XU, et al.
Published: (2015-10-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Papilledema: Could It Be an Important Clinical Sign of Leptomeningeal Metastasis?
by: Özge Arıcı Düz, et al.
Published: (2020-10-01)